178 results about "Glucagon-Like Peptides" patented technology

The invention relates to a bifidobacterium animalis subsp. Lactis YYSJ001 with a blood sugar reducing effect and application of the bifidobacterium animalis subsp. Lactis YYSJ001. The classification name of the strain is bifidobacterium animalis subsp. Lactis, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.33471. The invention further relates to a preparation method of the bifidobacterium animalis subsp. Lactis YYSJ001. The bacterial strain has good artificial gastric juice resistance, artificial intestinal juice resistance and intestinal tract adhesion ability, has an inhibition effect on numerous pathogenic bacteria such as escherichia coli, staphylococcus aureus, salmonella, klebsiella pneumoniae and quail chicken enterococcus, and can stimulate intestinal cells to generate glucagon-like peptide-1, so that the bacterial strain can be applied to preparation of various pathogenic bacteria. Diseases of diabetic mice can be effectively improved, and the compound can be used for preparing products for preventing and treating diabetes or assisting in reducing blood sugar.

The present application provides protease-resistant Glucagon-Like Peptide 1 (eGLP-1) peptides, and also provides protease-resistant dual agonist peptides against GLP-1R and GIPR, methods of making such peptides, as well as compositions comprising protease-resistant peptides and methods of treatment utilizing such peptides.

The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.

Provided are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

Methods for enhancing weight loss, or preventing or treating obesity or other conditions related thereto, such as diabetes, involve administering a GLP-1 agonist together with, or prior to, administering a mitochondrial uncoupler. Use of the uncoupler increases weight loss and enhances treatment of obesity and obesity-related medical conditions, such as by preventing weight regain after cessation of administration of the GLP-1 agonist.

The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.

The invention provides a preparation composition of a glucagon-like peptide-1 receptor agonist for nasal mucosa administration, and particularly relates to the technical field of biological medicine materials. The preparation composition mainly comprises a glucagon-like peptide-1 receptor stimulant, alkyl glycoside and phospholipid, wherein the ratio of the glucagon-like peptide-1 receptor stimulant to the alkyl glycoside to the phospholipid is (0.25-17.5): (0.25-10): (0.1-10) by mass. The active pharmaceutical ingredients in the preparation composition provided by the invention are delivered through nasal mucosa, directly enter blood circulation from an absorption part, can take effect quickly, have higher bioavailability, and improve the compliance of patients.

The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.

The present invention relates to improved uses of glucagon-like peptide-1 (GLP-1) peptides in oral therapy.

The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

Methods of treating metabolic disorders are disclosed herein, wherein the methods administer combinations of a sodium / glucose co- transporter 1 (SGLT1) inhibitor with a glucagon-like peptide agonist 1 (GLP 1), a gastric inhibitory peptide- 1 (GIP-1) analog, and / or d) a dual GLP-1-GIP-l receptor agonist.

The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.

The invention provides an application of synbiotics in preparation of a composition for improving glucagon-like peptide-1 (GLP-1). The composition comprises litchi polyphenol, probiotics and methionine. The probiotics comprise bifidobacterium animalis BCRC910645, bifidobacterium longum BCRC910812, or a combination of the bifidobacterium animalis BCRC910645 and the bifidobacterium longum BCRC910812, so that the content of the glucagon-like peptide-1 is increased.

Combinations of fatty acid synthesis (FASN) inhibitors and glucagon-like peptide-1 (GLP-1) agonists for treating NAFLD / MAFLD, NASH / MASH, liver fibrosis and / or liver cirrhosis.

A composition comprising a glucagon-like peptide 1 (GLP-1) agonist for sublingual or buccal administration, wherein the composition comprises one or more agents selected from the group consisting of; sodium glycodeoxycholate; sodium deoxycholate; carboxymethyl cellulose; sodium alginate; SNAC (salcaprozate sodium); a non-ionic ester alkoxylate (or alkanoic acid ester alkoxylate); and soy lecithin.

Provided herein are combinations comprising a glucagon-like peptide-1 receptor (GLP-1R) agonist and a thyroid hormone receptor beta (THRβ) agonist and methods comprising administering to a subject in need thereof such combinations.

The invention belongs to the technical field of medicines, and particularly relates to production and application of a glucagon-like peptide-1 analogue-coated bacterial outer membrane vesicle which is mainly applied to treatment of type 2 diabetes mellitus (T2DM) and obesity. The glucagon-like peptide-1 (GLP1) analogue-coated bacterial outer membrane vesicle load gene has a coding sequence as shown in the GLP1 analogue of SEQ ID NO: 1. The bacterial outer membrane vesicles wrapping the GLP1 analogue, which are successfully prepared by the invention, have potential clinical applicability and research value in treatment of type 2 diabetes mellitus (T2DM) and obesity.

The present disclosure relates to a GLP-1R agonist compound and use thereof, and specifically provides a compound represented by Formula I, or an isotope-labelled compound, a stereoisomer, or a pharmaceutically acceptable salt thereof, and use thereof as a medicament. The compound exhibits excellent agonistic effects and pharmacodynamic properties on GLP-1R and, as a modulator, is useful for manufacturing a medicament for the treatment, amelioration, or prevention of metabolic diseases and related diseases, thus having broad application prospects.

The present disclosure relates to dosage regimens for glucagon-like-peptide-2 (GLP-2) analogs, e.g., apraglutide, in a subject in need thereof, e.g., a subject with short bowel syndrome (SBS).

Provided herein are compounds comprising an ionic form of a GLP-1 receptor agonist, such as semaglutide, and a counterion thereof, additional esters and prodrug derivatives of semaglutide, and methods of use thereof.

The present invention relates to methods of treatment using acylated compounds and peptide hormones having dual agonist activity for the GLP-1 (glucagon-like peptide 1) and GLP-2 5 (glucagon-like peptide 2) receptors. In particular, the present invention relates to the administration of a dual GLP-1 / GLP-2 agonist peptide and amylin for modulating body weight and preventing or treating obesity and related conditions.

The present invention relates to a Korean microbiome-derived Clostridium butyricum strain having anti-obesity efficacy and a use thereof. The strain has an excellent effect of reducing the body weight and adipose tissue weight of experimental animals compared to a control group (strain-untreated) under high-fat diet conditions, has an excellent effect of reducing the content of total cholesterol, triglycerides, low-density lipoprotein (LDL), leptin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in serum, and has an excellent effect of reducing blood glucose and increasing the content of glucagon-like peptide-1 (GLP-1) in an oral glucose load test, and is thus expected to be effectively used as an ingredient in a composition for preventing, alleviating, or treating obesity and metabolic diseases caused by obesity.

The present invention relates to compositions comprising GLP-2 protein or variants thereof linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in the treatment of GLP-2-related conditions.

The present application relates to the pharmaceutical and biological fields, particularly relates to a polypeptide compound of general formula (I) with triple agonist activity on glucagon like peptide-1 receptor (GLP-1 R), glucose-dependent insulinotropic polypeptide receptor (GIP R), and glucagon receptor (GCG R), and use thereof in the treatment of metabolic syndrome.

There is provided a pharmaceutical formulation useful for the treatment of a metabolic disorder or condition, the pharmaceutical formulation comprising a plurality of particles suspended in a carrier system, the particles: (a) having an average diameter based on weight, quantity or volume of between about 10 nm and about 700 [mu] m; and (b) comprises a solid core comprising at least one glucagon-like peptide-1 receptor agonist or a pharmaceutically acceptable salt thereof, said solid core being at least partially coated by an inorganic material coating comprising a mixture of (i) zinc oxide; and (ii) one or more other metal oxides and / or metalloid oxides, wherein the atomic ratio ((i): (ii)) is at least about 1: 10 and up to and including about 10: 1. The mixed oxide coated particles are preferably synthesized by vapor phase coating techniques, such as atomic layer deposition. The formulations may provide delayed or sustained release of a glucagon-like peptide-1 receptor agonist to treat metabolic disorders or conditions, such as type 2 diabetes and / or obesity, without burst release effects. The glucagon-like peptide-1 receptor agonist is preferably a liraglutide (liraglutide), and the glucagon-like peptide-1 receptor agonist is preferably a liraglutide (liraglutide).

The invention relates to the field of microorganisms, in particular to application of a microbial strain in preparation of a medicine for preventing or treating metabolic diseases, the microbial strain belongs to Enterococcus canini, and the metabolic diseases comprise diabetes, obesity, obesity-related diseases and metabolic syndromes. According to the present invention, with the application of the Enterococcus canintestini, the target spots GPR120 and MC4R for the treatment of obesity diabetes can be significantly activated; the weight, fasting blood glucose, area under a glucose tolerance curve and area under an insulin tolerance curve of obese mice can be reduced, the content of free fatty acid in plasma, total cholesterol in liver and low-density lipoprotein-cholesterol in liver can be reduced, and the content of glucagon-like peptide-1 in plasma and the content of high-density lipoprotein-cholesterol in liver can be increased.

The invention relates to a cyclic peptide tyrosine-tyrosine conjugate coupled with a glucagon-like peptide 1 (GLP-1) fusion peptide and application of the cyclic peptide tyrosine-tyrosine conjugate. The present invention includes a conjugate comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods of use thereof. The novel conjugates are useful for preventing, treating, or ameliorating diseases and disorders disclosed herein.

The present invention relates to processes for obtaining glucagon-like-peptide-2 (GLP-2) analogues, such as glepaglutide. In particular, the processes described herein use a multi-step purification method of GLP-2 analogues synthesized by solid phase peptide synthesis (SPPS).